

BIBLIOGRAPHIE

- [1] Guilbert E, Bullet J, Sandali O, et al. Long-term rejection incidence and reversibility after penetrating and lamellar keratoplasty. *Am Ophthalmol* 2013;155(3):560–9. e2.
- [2] Ang M, Wilkins MR, Mehta JS, et al. Descemet membrane endothelial keratoplasty. *Br J Ophthalmol* 2016;100(1):15–21.
- [3] Niederkorn JY. Corneal transplantation and immune privilege. *Int Rev Immunol* 2013;32(1):57–67.
- [4] Niederkorn JY, Larkin DF. Immune privilege of corneal allografts. *Ocul Immunol Inflamm* 2010;18(3):162–71.
- [5] Coster DJ, Jessup CF, Williams KA. Mechanisms of corneal allograft rejection and regional immunosuppression. *Eye (Lond)* 2009;23(10):1894–7.
- [6] D'Orazio TJ, Niederkorn JY. A novel role for TGF-beta and IL-10 in the induction of immune privilege. *J Immunol* 1998;160(5):2089–98.
- [7] Taylor AW, Streilein JW, Cousins SW. Alpha-melanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon. *Neuroimmunomodulation* 1994;1(3):188–94.
- [8] Taylor AW, Streilein JW, Cousins SW. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. *J Immunol* 1994;153(3):1080–6.
- [9] Hegde S, Beauregard C, Mayhew E, et al. CD4(+) T-cell-mediated mechanisms of corneal allograft rejection: role of Fas-induced apoptosis. *Transplantation* 2005;79(1):23–31.
- [10] Whitsett CF, Stulting RD. The distribution of HLA antigens on human corneal tissue. *Invest Ophthalmol Vis Sci* 1984;25(5):519–24.
- [11] Apte RS, Niederkorn JY. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. *J Immunol* 1996;156(8):2667–73.
- [12] Apte RS, Mayhew E, Niederkorn JY. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. *Invest Ophthalmol Vis Sci* 1997;38(6):1277–82.
- [13] Apte RS, Sinha D, Mayhew E, et al. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. *J Immunol* 1998;160(12):5693–6.
- [14] Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. *J Immunol* 1986;136(10):3916–20.
- [15] Guilbert E, Laroche L, Borderie V. Rejection of corneal allografts. *J Fr Ophtalmol* 2011;34(5):331–48.
- [16] Panda A, Vanathi M, Kumar A, et al. Corneal graft rejection. *Surv Ophthalmol* 2007;52(4):375–96.
- [17] Coster DJ, Williams KA. Management of high-risk corneal grafts. *Eye (Lond)* 2003;17(8):996–1002.
- [18] Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. *Ophthalmology* 1994;101(9):1536–47.
- [19] Arentsen JJ. Corneal transplant allograft reaction: possible predisposing factors. *Trans Am Ophthalmol* 1983;81:361–402.
- [20] Hill JC. High risk corneal grafting. *Br J Ophthalmol* 2002;86(9):945.
- [21] Tariq M, Havens SJ. Corneal Graft Rejection. StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2018.
- [22] Trufanov SV, Subbot AM, Malozhen SA, et al. Risk factors, clinical presentations, prevention, and treatment of corneal graft rejection. *Vestnik Oftalmologii* 2016;132(6):108–16.
- [23] Williams KA, Roder D, Esterman A, et al. Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry. *Ophthalmology* 1992;99(3):403–14.
- [24] Reinhard T, Moller M, Sundmacher R. Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cyclosporin A. *Cornea* 1999;18(6):645–51.
- [25] Jonas JB, Rank RM, Budde WM. Immunologic graft reactions after allogenic penetrating keratoplasty. *Am J Ophthalmol* 2002;133(4):437–43.
- [26] Price Jr FW, Feng MT, Price MO. Evolution of endothelial keratoplasty: where are we headed? *Cornea* 2015;34(Suppl 10):S41–7.
- [27] Anshu A, Price MO, Price FW. Descemet's stripping endothelial keratoplasty: long-term graft survival and risk factors for failure in eyes with preexisting glaucoma. *Ophthalmology* 2012;119(10):1982–7.
- [28] Nguyen P, Khashabi S, Chopra V, et al. Descemet stripping with automated endothelial keratoplasty: A comparative study of outcome in patients with preexisting glaucoma. *Saudi J Ophthalmol* 2013;27(2):73–8.
- [29] Price MO, Jordan CS, Moore G, et al. Graft rejection episodes after Descemet stripping with endothelial keratoplasty: part two: the statistical analysis of probability and risk factors. *Br J Ophthalmol* 2009;93(3):391–5.
- [30] Parmar T, Ashar JN, Natarajan S. Graft Rejection following descemet stripping automated endothelial keratoplasty: features, risk factors, and outcomes. *Am J Ophthalmol* 2012;154(1):211. author reply 211–2.
- [31] Wu EI, Ritterband DC, Yu G, et al. Graft rejection following descemet stripping automated endothelial keratoplasty: features, risk factors, and outcomes. *Am J Ophthalmol* 2012;153(5):949–57. e1.
- [32] Mitry D, Bhogal M, Patel AK, et al. Descemet stripping automated endothelial keratoplasty after failed penetrating keratoplasty: survival, rejection risk, and visual outcome. *JAMA Ophthalmol* 2014;132(6):742–9.
- [33] Monnereau C, Bruinsma M, Ham L, et al. Endothelial cell changes as an indicator for upcoming allograft rejection following descemet membrane endothelial keratoplasty. *Am J Ophthalmol* 2014;158(3):485–95.
- [34] Zygoura V, Baydoun L, Monnereau C, et al. Dark endothelial spots after Descemet membrane endothelial keratoplasty may appear as recurrent Fuchs dystrophy or herald graft failure or rejection. *Cornea* 2017;36(12):1480–5.
- [35] Paufique L, Sourdille GP, Offret G. Les greffes de la cornée. *Arch Ophtalmol Rev Gén Ophtalmol* 1949;9(1):53–5.
- [36] Khodadoust AA, Silverstein AM. Transplantation and rejection of individual cell layers of the cornea. *Invest Ophthalmol* 1969;8(2):180–95.
- [37] Chan CM, Wong TY, Yeong SM, et al. Penetrating keratoplasty in the Singapore National Eye Centre and donor cornea acquisition in the Singapore Eye Bank. *Ann Acad Med Singapore* 1997;26(4):395–400.
- [38] Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. *Arch Ophthalmol (Chicago)* 1981;99(4):599–604.
- [39] Krachmer JH, Alldredge OC. Subepithelial infiltrates: a probable sign of corneal transplant rejection. *Arch Ophthalmol* 1978;96(12):2234–7.
- [40] Shapiro MBMM, Krachmer JH. Rejection. In: Bright B (Ed). Corneal surgery, theory, technique and tissues. 2nd ed. St-Louis: Mosby; 1997. p. 254–68.
- [41] Claerhout I, Beele H, De Bacquer D, et al. Factors influencing the decline in endothelial cell density after corneal allograft rejection. *Invest Ophthalmol Vis Sci* 2003;44(11):4747–52.
- [42] Larkin DF. Corneal allograft rejection. *Br J Ophthalmol* 1994;78(8):649–52.
- [43] Naacke HG, Borderie VM, Bourcier T, et al. Outcome of corneal transplantation rejection. *Cornea* 2001;20(4):350–3.
- [44] McDonnell PJ, Enger C, Stark WJ, et al. Corneal thickness changes after high-risk penetrating keratoplasty. Collaborative Corneal Transplantation Study Group. *Arch Ophthalmol* 1993;111(10):1374–81.
- [45] Borderie VM, Touzeau O, Bourcier T, et al. Outcome of graft central thickness after penetrating keratoplasty. *Ophthalmology* 2005;112(4):626–33.
- [46] Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. *Ophthalmology* 1991;98(3):329–33.
- [47] Hill JC, Maske R, Watson PG. The use of a single pulse of intravenous methylprednisolone in the treatment of corneal graft rejection. A preliminary report. *Eye (Lond)* 1991;5(Pt 4):420–4.
- [48] Hill JC, Ivey A. Corticosteroids in corneal graft rejection: double versus single pulse therapy. *Cornea* 1994;13(5):383–8.

- [49] Costa DC, Castro RS, Camargo MS, et al. Corneal allograft rejection: topical treatment vs. pulsed intravenous methylprednisolone - ten years' result. *Arq Bras Oftalmol* 2008;71(1):57-61.
- [50] Hudde T, Minassian DC, Larkin DF. Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. *Br J Ophthalmol* 1999;83(12):1348-52.
- [51] Costa DC, de Castro RS, Kara-Jose N. Case-control study of subconjunctival triamcinolone acetate injection vs intravenous methylprednisolone pulse in the treatment of endothelial corneal allograft rejection. *Eye (Lond)* 2009;23(3):708-14.
- [52] Goyal S, Uwaydat SH. Multiquadrant subtenon triamcinolone injection for acute corneal graft rejection: a case report. *Case Rep Ophthalmol* 2017;8(2):308-13.
- [53] Young AL, Rao SK, Cheng LL, et al. Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience. *Eye (Lond)* 2002;16(3):304-8.
- [54] Poon A, Constantinou M, Lamoureux E, et al. Topical cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. *Clin Exp Ophthalmol* 2008;36(5):415-21.
- [55] Nguyen NX, Seitz B, Martus P, et al. Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. *Am J Ophthalmol* 2007;144(2):318-9.
- [56] Price MO, Price Jr FW. Efficacy of topical cyclosporine 0.05 % for prevention of cornea transplant rejection episodes. *Ophthalmology* 2006;113(10):1785-90.
- [57] Ziaei M, Manzouri B. Topical cyclosporine in corneal transplantation. *Cornea* 2015;34(1):110-5.
- [58] Sinha R, Jhanji V, Verma K, et al. Efficacy of topical cyclosporine A 2 % in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. *Graefes Arch Clin Exp Ophthalmol* 2010;248(8):1167-72.
- [59] Dhaliwal JS, Mason BF, Kaufman SC. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. *Cornea* 2008;27(4):488-93.
- [60] Birnbaum F, Bohringer D, Sokolovska Y, et al. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty : a retrospective study. *Transplantation* 2005;79(8):964-8.
- [61] Price MO, Scameo A, Feng MT, et al. Descemet's membrane endothelial keratoplasty: risk of immunologic rejection episodes after discontinuing topical corticosteroids. *Ophthalmology* 2016;123(6):1232-6.
- [62] Price MO, Price Jr FW, Kruse FE, et al. Randomized comparison of topical prednisolone acetate 1 % versus fluorometholone 0.1 % in the first year after descemet membrane endothelial keratoplasty. *Cornea* 2014;33(9):880-6.